Drs Samuel Klempner and Haeseong Park discuss emerging biomarkers and novel therapies for esophageal cancer, including new data from ASCO.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999886. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Esophageal Cancer https://emedicine.medscape.com/article/277930-overview

Prospective Randomized Multicenter Phase III Trial Comparing Perioperative Chemotherapy (FLOT Protocol) to Neoadjuvant Chemoradiation (CROSS Protocol) in Patients With Adenocarcinoma of the Esophagus (ESOPEC Trial) https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.17_suppl.LBA1

Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer https://pubmed.ncbi.nlm.nih.gov/30028179/

Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer (KEYNOTE-859): A Multicentre, Randomised, Double-Blind, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/37875143/

First-Line Nivolumab Plus Chemotherapy Versus Chemotherapy Alone for Advanced Gastric, Gastro-Oesophageal Junction, and Oesophageal Adenocarcinoma (CheckMate 649): A Randomised, Open-Label, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/34102137/

FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial https://pubmed.ncbi.nlm.nih.gov/32469386/

Targeting CLDN18.2 in Cancers of the Gastrointestinal Tract: New Drugs and New Indications https://pubmed.ncbi.nlm.nih.gov/36969060/

Targeting FGFR2 Positive Gastroesophageal Cancer: Current and Clinical Developments https://pubmed.ncbi.nlm.nih.gov/36238135/

The KEYNOTE-811 Trial of Dual PD-1 and HER2 Blockade in HER2-Positive Gastric Cancer https://pubmed.ncbi.nlm.nih.gov/34912120/

Dose-Escalation and Dose-Expansion Study of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Patients (pts) With Advanced/Metastatic HER2+ Gastric Cancer (GC)/Gastroesophageal Junction Adenocarcinoma (GEJA): DESTINY-Gastric03 https://ascopubs.org/doi/10.1200/JCO.2022.40.4_suppl.295

Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials https://pubmed.ncbi.nlm.nih.gov/37291608/

Zolbetuximab Plus mFOLFOX6 in Patients With CLDN18.2-Positive, HER2-Negative, Untreated, Locally Advanced Unresectable or Metastatic Gastric or Gastro-Oesophageal Junction Adenocarcinoma (SPOTLIGHT): A Multicentre, Randomised, Double-Blind, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/37068504/

The RENAISSANCE (AIO-FLOT5) Trial: Effect of Chemotherapy Alone vs. Chemotherapy Followed by Surgical Resection on Survival and Quality of Life in Patients With Limited-Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction - a Phase III Trial of the German AIO/CAO-V/CAOGI https://pubmed.ncbi.nlm.nih.gov/29282088/